Literature DB >> 21466357

The significance of "indefinite for dysplasia" grading in Barrett metaplasia.

Mamoun Younes1, Gregory Y Lauwers, Atilla Ertan, Gulchin Ergun, Ray Verm, Margaret Bridges, Karen Woods, Frank Meriano, Carl Schmulen, Craig Johnson, Alberto Barroso, Jim Schwartz, John McKechnie, Juan Lechago.   

Abstract

CONTEXT: For a confident diagnosis of dysplasia in Barrett metaplasia, the epithelial atypia should also involve the surface epithelium. However, pathologists are often faced with biopsies where the crypts show dysplasia, but the surface epithelium is either uninvolved or unevaluable. We previously grouped these cases with indefinite for dysplasia (IND).
OBJECTIVE: To determine the clinical significance of IND grading in Barrett metaplasia.
DESIGN: All biopsies from 276 prospectively followed patients with Barrett metaplasia, who did not have high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) on initial biopsy, were graded as negative for dysplasia, IND, low-grade dysplasia (LGD), HGD, and EAC. Biopsies with multifocal IND or LGD were graded as INDM or LGDM, respectively.
RESULTS: Only 3 of 193 patients (2%) with an initial diagnosis of negative for dysplasia and only 1 of 48 patients (2%) diagnosed with IND progressed to HGD or EAC. By contrast, 1 of 7 patients (14%) with INDM, 2 of 21 (10%) with LGD, and 1 of 7 (14%) with LGDM progressed to HGD or EAC. There was no significant difference in progression rate between patients with an initial diagnosis of negative for dysplasia and those diagnosed IND nor were there significant differences among patients with initial diagnoses of INDM, LGD, or LGDM. Kaplan-Meier analysis showed that patients with INDM, LGD, or LGDM on initial biopsy (group 1) were more likely to progress to HGD or EAC than were those patients who were diagnosed negative for dysplasia or IND (group 2; log-rank test, P < .001).
CONCLUSIONS: Multifocal IND in an esophageal biopsy from a patient with Barrett metaplasia has the same clinical implication as LGD.

Entities:  

Mesh:

Year:  2011        PMID: 21466357     DOI: 10.5858/2010-0097-OA.1

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  11 in total

Review 1.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

2.  Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.

Authors:  M Ma; S Shroff; M Feldman; M DeMarshall; C Price; A Tierney; G W Falk
Journal:  Dis Esophagus       Date:  2017-03-01       Impact factor: 3.429

Review 3.  Barrett's esophagus in 2016: From pathophysiology to treatment.

Authors:  Irene Martinucci; Nicola de Bortoli; Salvatore Russo; Lorenzo Bertani; Manuele Furnari; Anna Mokrowiecka; Ewa Malecka-Panas; Vincenzo Savarino; Edoardo Savarino; Santino Marchi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

Review 4.  Barrett's oesophagus: frequency and prediction of dysplasia and cancer.

Authors:  Gary W Falk
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-01-20       Impact factor: 3.043

5.  Dysplasia discrimination in intestinal-type neoplasia of the esophagus and colon via digital image analysis.

Authors:  David R Martin; David R Braxton; Alton B Farris
Journal:  Virchows Arch       Date:  2016-08-05       Impact factor: 4.064

Review 6.  Surveillance for low-grade dysplastic Barrett's oesophagus: one size fits all?

Authors:  Giovanni Zaninotto; Cathy Bennett
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

7.  ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.

Authors:  Nicholas J Shaheen; Gary W Falk; Prasad G Iyer; Lauren B Gerson
Journal:  Am J Gastroenterol       Date:  2015-11-03       Impact factor: 10.864

Review 8.  BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia.

Authors:  Cathy Bennett; Paul Moayyedi; Douglas A Corley; John DeCaestecker; Yngve Falck-Ytter; Gary Falk; Nimish Vakil; Scott Sanders; Michael Vieth; John Inadomi; David Aldulaimi; Khek-Yu Ho; Robert Odze; Stephen J Meltzer; Eamonn Quigley; Stuart Gittens; Peter Watson; Giovanni Zaninotto; Prasad G Iyer; Leo Alexandre; Yeng Ang; James Callaghan; Rebecca Harrison; Rajvinder Singh; Pradeep Bhandari; Raf Bisschops; Bita Geramizadeh; Philip Kaye; Sheila Krishnadath; M Brian Fennerty; Hendrik Manner; Katie S Nason; Oliver Pech; Vani Konda; Krish Ragunath; Imdadur Rahman; Yvonne Romero; Richard Sampliner; Peter D Siersema; Jan Tack; Tony C K Tham; Nigel Trudgill; David S Weinberg; Jean Wang; Kenneth Wang; Jennie Y Y Wong; Stephen Attwood; Peter Malfertheiner; David MacDonald; Hugh Barr; Mark K Ferguson; Janusz Jankowski
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

9.  Imaging heterogeneity in the mitochondrial redox state of premalignant pancreas in the pancreas-specific PTEN-null transgenic mouse model.

Authors:  He N Xu; Shoko Nioka; Lin Z Li
Journal:  Biomark Res       Date:  2013-01-17

10.  "Indefinite for Dysplasia" in Barrett's Esophagus: Inflammation and DNA Content Abnormality are Significant Predictors of Early Detection of Neoplasia.

Authors:  Won-Tak Choi; Mary J Emond; Peter S Rabinovitch; Joseph Ahn; Melissa P Upton; Maria Westerhoff
Journal:  Clin Transl Gastroenterol       Date:  2015-03-12       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.